Anzeige
Mehr »
Montag, 23.02.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Verteidigung: Drohnen-Player vor nächstem Bewertungssprung?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
151 Leser
Artikel bewerten:
(1)

Volta Labs Inc.: Volta Labs and Watchmaker Genomics Partner to Introduce Callisto Complete Kit for DNA EF Library Prep at AGBT 2026

BOSTON and BOULDER, Colo., Feb. 23, 2026 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting 2026 in Orlando, FL, Volta Labs, a leader in next-generation sequencing (NGS) sample preparation automation, today announced the launch of the Callisto Complete Kit for DNA EF Library Prep. The new solution pairs Watchmaker Genomics' best-in-class NGS sample preparation chemistry with Volta's digital fluidics automation to deliver a fully automated, PCR-free whole genome sequencing (WGS) library preparation workflow.

Callisto Complete Kit for DNA EF Library Prep (Powered by Watchmaker)

As whole genome sequencing continues to expand across clinical research and translational settings, PCR-free workflows are increasingly preferred to minimize amplification bias, reduce sequencing artifacts, and enable more uniform genome coverage, particularly in GC-rich regions. However, executing PCR-free library preparation demands precision and reproducibility, making automation critical for labs seeking consistent results without increasing staffing burden. By eliminating manual liquid handling and reducing operator variability, the Callisto Complete Kit enables laboratories to generate reproducible, high-quality libraries while freeing technical staff to focus on higher-value work.

"We designed Callisto to make sequencing sample preparation simpler and more accessible," said Udayan Umapathi, CEO of Volta Labs. "With the Callisto Complete Kit for DNA EF Library Prep, powered by Watchmaker chemistry, labs can run PCR-free whole genome sequencing workflows in a push-button format, delivering consistent, high-quality results in a practical mid-throughput range."

"PCR-free whole genome sequencing demands both high-performance chemistry and workflow precision," said Trey Foskett, CEO of Watchmaker Genomics. "For clinical and translational laboratories that require push-button solutions with dependable performance but do not operate at a high-throughput scale, the Callisto Complete Kit offers a simple and streamlined path to implementing PCR-free WGS with confidence."

To mark the launch, Volta Labs and Watchmaker Genomics will host a joint in suite presentation at AGBT 2026 on February 24 at 8:30 a.m. in the Fulton Suite, where attendees can learn more about the Callisto Complete Kit for DNA EF Library Prep, see the automated PCR-free WGS workflow in action, and hear directly from both teams.

About Volta Labs

Volta Labs is pioneering a new future of sequencing sample preparation by combining digital fluidics, modular workflows, and full walk-away automation in a single platform. Callisto enables high-quality, reproducible NGS library preparation for whole-genome, targeted, and custom applications. Volta Labs is headquartered in Boston, Massachusetts.

About Watchmaker Genomics

Watchmaker Genomics is a life sciences company focused on developing high-performance tools that empower genomic research and clinical applications. Leveraging expertise in protein engineering and next-generation sequencing, Watchmaker delivers precision reagents and platforms that enable superior accuracy, efficiency, and cost-effectiveness in molecular analysis. The company is dedicated to advancing breakthrough technologies to support innovations in cancer detection, epigenetics, and liquid biopsy applications.

Media Contacts

Volta Labs
Nicole Ellis Ovadia
Director of Strategic Marketing
novadia@voltalabs.co

Watchmaker Genomics
Jen Pavlica
Associate Director, Product Marketing
jen.pavlica@watchmakergenomics.com

Volta Labs, a genomics applications company, is transforming the way biological research and analyses are performed with a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation.

Photo - https://mma.prnewswire.com/media/2918037/Volta_Labs.jpg
Logo - https://mma.prnewswire.com/media/2611556/VoVolta_Labs_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/volta-labs-and-watchmaker-genomics-partner-to-introduce-callisto-complete-kit-for-dna-ef-library-prep-at-agbt-2026-302694404.html

© 2026 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.